Australia unites taking small steps to make a big difference for melanoma research
23 March 2016
Melanoma March events have been an outstanding success across the country, with more than 6,000 dedicated supporters turning out for marches across 23 locations over the last month. Well over $600,000 has been raised, with two weeks of the campaign still remaining.
The Melbourne event, held early in March, attracted around 1,500 supporters, while 800 turned out for the Brisbane march last weekend. Over 700 supporters, including NSW Premier Mike Baird and rugby legend John Eales, braved the ominous clouds at Manly, while the inaugural march in Penrith attracted 500 people.
A team of volunteers and MIA staff ensured the events ran smoothly, arriving on site well before dawn to help set up, managing registrations, selling merchandise and staying back to pack up after events. MIA’s clinicians also attended events sharing their clinical insights and experiences with local crowds.
MIA’s CEO Carole Renouf who walked at the Wollongong and Manly marches said: “It takes an incredible amount of work behind the scenes to ensure events go to plan. We couldn’t do it without our incredible volunteers including staff members who took time out of their weekends to help. It was a real team effort and it was fantastic to see so many staff involved.
“I’d also like to thank our patients who bravely shared their stories with media and spoke at events. I was moved and inspired to hear about their experiences. They are the reason we do what we do.”
The final Melanoma March will be in Darwin on Sunday 10 April.
Congratulations to Professor Georgina Long
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
Uniting our global researchers for melanoma
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care go digital
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Awards and honours for our talented researchers
Congratulations are in order for two of our talented researchers.
5 Minutes With Prof Richard Scolyer
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Research spotlight: High Risk Clinic
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
Learning from the best in the world
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
Uniting the world for a cure
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
A Day in the Life of... Michelle Peranec
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Wildfire Award helps ignite new melanoma research
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Opinion: Fighting the Resistance
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
5 Minutes With A/Prof Jennifer Wargo
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott awarded for outstanding cancer research
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
Community invests in MIA's new trial
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
New trial giving options
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Melanoma research summary from ASCO
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
Updated privacy policy
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Can cognitive technology assist with melanoma identification?
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
'4 Questions With...' Series
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
Stop the Spread campaign shortlisted
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.